tadalafil has been researched along with Lung Diseases, Interstitial in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Humbert, M; Weatherald, J | 1 |
| Ishii, H; Kinoshita, Y; Kushima, H; Nabeshima, K; Watanabe, K | 1 |
| Behr, J; Geiseler, J; Huppmann, P; Ihle, F; Leuchte, HH; Meis, T; Neurohr, C; Tufman, A; von Wulffen, W; Zimmermann, GS | 1 |
3 other study(ies) available for tadalafil and Lung Diseases, Interstitial
| Article | Year |
|---|---|
PDE5 to keep them alive: The use of phosphodiesterase type-5 inhibitors in severe pulmonary hypertension associated with interstitial lung disease.
Topics: Carbolines; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Phosphodiesterase 5 Inhibitors; Phosphoric Diester Hydrolases; Purines; Sildenafil Citrate; Tadalafil | 2023 |
Lower-lobe predominant pleuroparenchymal fibroelastosis.
Topics: Adrenal Cortex Hormones; Aged; Autopsy; Dermatomyositis; Fatal Outcome; Female; Humans; Immunosuppressive Agents; Lung; Lung Diseases, Interstitial; Parenchymal Tissue; Phosphodiesterase 5 Inhibitors; Pleura; Pleural Diseases; Pulmonary Fibrosis; Tadalafil; Tomography, X-Ray Computed | 2019 |
Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors.
Topics: Aged; Aged, 80 and over; Carbolines; Female; Follow-Up Studies; Hemodynamics; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Male; Middle Aged; Natriuretic Peptide, Brain; Phosphodiesterase 5 Inhibitors; Pilot Projects; Piperazines; Purines; Respiratory Function Tests; Sildenafil Citrate; Sulfonamides; Tadalafil; Walking | 2014 |